KRAS and neoplasm: The mutation rate of other oncogenes was not significantly different between the LGSCs and SBTs; however there was a trend towards a lower frequency of BRAF and KRAS mutants in the LGSCs and a higher rate of “wildtype” tumours, where no oncogenic mutation was identified (Table 2).